Ribometrix Names William S. Marshall, Ph.D., as CEO to Drive Breakthrough RNA-Targeting Therapeutics

Durham, NC, January 09, 2025 (Globe newswire) -- Ribometrix has appointed Dr. William S. Marshall as CEO and Dr. Katie Warner as CSO, marking a pivotal moment for the company as it advances its proprietary RNA-targeting small-molecule platform. Dr. Marshall, a seasoned biotech leader and innovator, brings experience from leading roles at miRagen, Thermo Fisher Scientific, and Amgen, alongside a prolific record of scientific contributions. Under his leadership, Ribometrix aims to capitalize on its groundbreaking RNA-binding technology to develop therapies that inhibit disease-causing protein expression.

Read full article here.